Mumbai — Agrochemical major Sharda Cropchem Ltd. is making waves in the market following notable updates in its shareholding pattern and a bullish research report from domestic brokerage Anand Rathi.
Key Highlights
- Ace Investor Shareholding: Renowned investor Dolly Khanna, who held a 1.09% stake ($9,82,178\text{ shares}$) in the quarter ended March 2026, saw her holding drop below the reportable $1%$ threshold (reflected as Nil) in the June 2026 shareholding pattern.
- Brokerage Recommendation: In a research note dated July 30, 2026, Anand Rathi Shares and Stock Brokers maintained a Buy rating on the stock with a Target Price (TP) of ₹1,350, representing a +64.68% potential upside from its current levels (~₹820).
- Valuation & Balance Sheet: The stock trades at an attractive valuation of 11x FY27e and 10x FY28e earnings, backed by a net cash balance sheet exceeding ₹750 crore (>₹7.5b).
- Return Metrics: Supported by strong volume recovery and margin resilience, return ratios remain robust with RoE at 25% and RoCE at 30%.
Investor Movements: Dolly Khanna’s Portfolio Adjustment
Corporate filings for the quarter ended June 30, 2026, reveal that Dolly Khanna—known for identifying high-growth opportunities in midcap and smallcap chemical and manufacturing spaces—no longer features in the list of shareholders holding $1%$ or more in Sharda Cropchem.
While a public disclosure drop to “Nil” indicates her stake fell below the mandatory $1%$ threshold, market observers often monitor such moves closely. Despite the institutional/HNI shift, fundamental analysts view the company’s operating performance as entering a key expansion phase.
Brokerage Thesis: Anand Rathi’s Bullish Case
Anand Rathi’s updated report highlights several growth drivers sustaining momentum for Sharda Cropchem:
1. Volume Revival Driving Earnings Growth
After navigating global agrochemical channel destocking over previous cycles, Sharda Cropchem is seeing steady volume recovery across key export geographies, including Europe, North America, and Latin America. Management guidance points to sustainable volume expansion driven by new product dossier registrations.
2. Deep Margin & Valuation Safety
At 11x FY27e and 10x FY28e price-to-earnings ratios, the stock trades at a notable discount to historical averages and industry peers, offering a wide margin of safety.
| Metric | Target / Ratio |
|---|---|
| Target Price (TP) | ₹1,350 (+64.68% upside) |
| FY27e P/E | 11x |
| FY28e P/E | 10x |
| Net Cash Balance Sheet | > ₹750 Crore (> ₹7.5b) |
| Return on Equity (RoE) | ~25% |
| Return on Capital Employed (RoCE) | ~30% |
3. Balance Sheet Strength & Cash Generation
Sharda Cropchem maintains a debt-free status with a net cash position exceeding ₹750 crore. This cash pile enables continuous investment in global dossier filings without straining working capital or diluting return metrics.
Outlook
While superstar investor portfolio changes can trigger short-term sentiment shifts, Anand Rathi’s fundamental outlook emphasizes the core operational turnaround. With 25% RoE and 30% RoCE, strong liquidity, and volume-led revenue growth, the stock remains a compelling long-term candidate with a projected target of ₹1,350.